Scrip
US FDA panel to review InterMune's pirfenidone for idiopathic pulmonary fibrosis
02 February 2010
Nancy Faigen
The US FDA's pulmonary-allergy drugs advisory committee will meet on March 9th to review
InterMune's NDA for its investigational idiopathic pulmonary fibrosis (IPF) treatment, pirfenidone.
Just last month, the agency granted the compound priority status – with a user fee date set for May 4th....
Please Login to read the full article.
02 February 2010
Nancy Faigen
Just last month, the agency granted the compound priority status – with a user fee date set for May 4th....
Please Login to read the full article.
RELATED CONTENT
COMMENT
Other Informa Comment
FEATURES
- Face-to-Face: Trophos - The French firm that hooked Actelion
- Face to Face with Sandoz's "growth guy" Jeff George
EVENTS
01 January 1970
London, UK
01 January 1970
San Diego, US
01 January 1970
Providence, Rhode Island, and San Francisco, California
JOB OF THE WEEK
Promote your vacancy here
